IL28B genotyping and treatment of HCV infected subjects

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33152198" target="_blank" >RIV/61989592:15110/14:33152198 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/14:#0000811

Výsledek na webu

<a href="http://dx.doi.org/10.5372/1905-7415.0804.313" target="_blank" >http://dx.doi.org/10.5372/1905-7415.0804.313</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5372/1905-7415.0804.313" target="_blank" >10.5372/1905-7415.0804.313</a>

Jazyk výsledku

angličtina

Název v původním jazyce

IL28B genotyping and treatment of HCV infected subjects

Popis výsledku v původním jazyce

Background: Chronic hepatitis C is a common cause of advanced liver disease and appropriate treatment has been complex and a challenge. Reaction of individual genotypes to classical pegylated interferon-ribavirin therapy differs and no success has been achieved in some even after repeated therapy cycles. New types of so called directly acting antivirals (DAAs) are hopeful, as shown in many recent clinical studies, and triple therapy regimens involving DAA are becoming the new standard of care. Objective: To summarize knowledge about the relationship between HCV therapeutic regimens and the genetic background of the host represented by interleukin 28B (IL28B) gene polymorphisms. In the first part, the host basic mechanisms in specific and innate immunity are introduced. The IL28B genotype and its role in the course of HCV treatment are described in the second part. Methods: We searched and summarized publications on HCV therapeutic regimens and host IL28B polymorphisms. Results: Compare

Název v anglickém jazyce

IL28B genotyping and treatment of HCV infected subjects

Popis výsledku anglicky

Background: Chronic hepatitis C is a common cause of advanced liver disease and appropriate treatment has been complex and a challenge. Reaction of individual genotypes to classical pegylated interferon-ribavirin therapy differs and no success has been achieved in some even after repeated therapy cycles. New types of so called directly acting antivirals (DAAs) are hopeful, as shown in many recent clinical studies, and triple therapy regimens involving DAA are becoming the new standard of care. Objective: To summarize knowledge about the relationship between HCV therapeutic regimens and the genetic background of the host represented by interleukin 28B (IL28B) gene polymorphisms. In the first part, the host basic mechanisms in specific and innate immunity are introduced. The IL28B genotype and its role in the course of HCV treatment are described in the second part. Methods: We searched and summarized publications on HCV therapeutic regimens and host IL28B polymorphisms. Results: Compare

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Asian Biomedicine

ISSN

1905-7415

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

TH - Thajské království

Počet stran výsledku

8

Strana od-do

445-452

Kód UT WoS článku

000345883100002

EID výsledku v databázi Scopus

—